Dong Kim - 25 Mar 2022 Form 4/A Insider Report for UroGen Pharma Ltd. (URGN)

Reporting relationship: Chief Financial Officer
Issuer ticker: URGN
Reported as of: 25 Mar 2022
Net transaction value: $0
SEC form: 4/A
Accepted by SEC: 12 Feb 2024, 17:43:15 UTC
Original report date: 29 Mar 2022
Next SEC filing: 02 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Jason D. Smith, Attorney-in-Fact

Key filing fact

Dong Kim filed Form 4/A for UroGen Pharma Ltd. (URGN) on 12 Feb 2024.

Key facts

This page summarizes Dong Kim's Form 4/A filing for UroGen Pharma Ltd. (URGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Feb 2024, 17:43.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

URGN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 25 Mar 2022
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 20,000
Exercise price: $8.61
Footnotes: F1, F2, F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

One third of the shares underlying the stock option will vest on each of March 25, 2023, March 25, 2024 and March 25, 2025.

Footnote F2

This amendment corrects and restates the number of derivative securities acquired reported in the original Form 4 filed on March 29, 2022.

Footnote F3

This amendment corrects and restates the expiration date reported in the original Form 4 filed on March 29, 2022.

Footnote F4

This amendment corrects and restates the amount of securities underlying derivative security reported in the original Form 4 filed on March 29, 2022.

Footnote F5

This amendment corrects and restates the number of derivative securities beneficially owned following reported transaction reported in the original Form 4 filed on March 29, 2022.